Pulmonary cytology in the posttherapeutic monitoring of patients with bronchogenic carcinoma.
A study of 113 patients with histologically confirmed bronchogenic carcinoma and survival for at least 18 months was performed. Posttherapeutic cytologic specimens were submitted for only 52.2% (59/113), and for only 8.5% (5/59) of the individuals was specimen procurement related to clinic visits. Yet, when utilized as a diagnostic procedure for the hospitalized patient, a positive cytodiagnosis was made on 55.6% (15/27) of the patients with recurrent carcinoma, in 61.1% (11/18) with persistent disease and in all 5 patients with a metachronous primary bronchogenic carcinoma. Cytologic diagnoses of cancer compared favorably with concurrent histologic interpretations of biopsies and radiologic observations of chest films.
Korfhage
L
L
Broghamer
W L
WL
Richardson
M E
ME
Parker
J E
JE
Gilkey
C M
CM
D001980:Bronchi / Q000378:metabolism / Q000473:pathology; D002283:Carcinoma, Bronchogenic / Q000378:metabolism / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D006801:Humans; D008168:Lung / Q000473:pathology*; D008175:Lung Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008991:Monitoring, Physiologic / Q000379:methods*; D013902:Radiography, Thoracic; D007507:Therapeutic Irrigation; D013899:Thoracic Neoplasms / Q000000981:diagnostic imaging; D013997:Time Factors; D014132:Trachea / Q000378:metabolism / Q000473:pathology